GU Cancer

‘Outrageous’: the best treatment for bladder cancer is out of production

Oncologists must continue to ration the critical bladder cancer therapy bacillus Calmette-Guérin (BCG) among high-risk patients as the global shortage of the immunotherapy is set to continue well into 2021. The bacteria-based immunotherapy, which has been standard care for non muscular invasive bladder cancer for more than three decades, beats out both surgery and chemotherapy ...

Already a member?

Login to keep reading.

© 2021 the limbic